KR102500868B1 - 항-cd19 항체 및 bcl-2 억제제의 조합 및 이의 용도 - Google Patents

항-cd19 항체 및 bcl-2 억제제의 조합 및 이의 용도 Download PDF

Info

Publication number
KR102500868B1
KR102500868B1 KR1020197012532A KR20197012532A KR102500868B1 KR 102500868 B1 KR102500868 B1 KR 102500868B1 KR 1020197012532 A KR1020197012532 A KR 1020197012532A KR 20197012532 A KR20197012532 A KR 20197012532A KR 102500868 B1 KR102500868 B1 KR 102500868B1
Authority
KR
South Korea
Prior art keywords
ser
leu
pharmaceutical composition
val
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197012532A
Other languages
English (en)
Korean (ko)
Other versions
KR20190075942A (ko
Inventor
잔 엔델
콘스탄틴 페트로포울로스
피터 켈레멘
라이너 박스해머
마르쿠스 루케르트
Original Assignee
모르포시스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모르포시스 아게 filed Critical 모르포시스 아게
Priority to KR1020237005018A priority Critical patent/KR20230028571A/ko
Publication of KR20190075942A publication Critical patent/KR20190075942A/ko
Application granted granted Critical
Publication of KR102500868B1 publication Critical patent/KR102500868B1/ko
Assigned to 인사이트 코포레이션 reassignment 인사이트 코포레이션 권리의 전부이전등록 Assignors: 모르포시스 아게
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020197012532A 2016-10-28 2017-10-27 항-cd19 항체 및 bcl-2 억제제의 조합 및 이의 용도 Active KR102500868B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237005018A KR20230028571A (ko) 2016-10-28 2017-10-27 항-cd19 항체 및 bcl-2 억제제의 조합 및 이의 용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16196184.2 2016-10-28
EP16196184 2016-10-28
PCT/EP2017/077654 WO2018078123A1 (en) 2016-10-28 2017-10-27 Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237005018A Division KR20230028571A (ko) 2016-10-28 2017-10-27 항-cd19 항체 및 bcl-2 억제제의 조합 및 이의 용도

Publications (2)

Publication Number Publication Date
KR20190075942A KR20190075942A (ko) 2019-07-01
KR102500868B1 true KR102500868B1 (ko) 2023-02-16

Family

ID=57218739

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197012532A Active KR102500868B1 (ko) 2016-10-28 2017-10-27 항-cd19 항체 및 bcl-2 억제제의 조합 및 이의 용도
KR1020237005018A Ceased KR20230028571A (ko) 2016-10-28 2017-10-27 항-cd19 항체 및 bcl-2 억제제의 조합 및 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237005018A Ceased KR20230028571A (ko) 2016-10-28 2017-10-27 항-cd19 항체 및 bcl-2 억제제의 조합 및 이의 용도

Country Status (25)

Country Link
US (1) US12358983B2 (https=)
EP (2) EP3903821A1 (https=)
JP (3) JP7094950B2 (https=)
KR (2) KR102500868B1 (https=)
CN (2) CN118045175A (https=)
AU (2) AU2017348624B2 (https=)
BR (1) BR112019008244A2 (https=)
CA (1) CA3037246A1 (https=)
CY (1) CY1124648T1 (https=)
DK (1) DK3532098T3 (https=)
ES (1) ES2871574T3 (https=)
HR (1) HRP20210838T1 (https=)
HU (1) HUE054496T2 (https=)
IL (3) IL301786B2 (https=)
LT (1) LT3532098T (https=)
MX (2) MX2019004942A (https=)
PL (1) PL3532098T3 (https=)
PT (1) PT3532098T (https=)
RS (1) RS62036B1 (https=)
RU (1) RU2756405C2 (https=)
SG (1) SG10202104036QA (https=)
SI (1) SI3532098T1 (https=)
SM (1) SMT202100347T1 (https=)
WO (1) WO2018078123A1 (https=)
ZA (1) ZA201903302B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100541T1 (it) 2015-08-21 2021-11-12 Morphosys Ag Combinazioni e loro usi
IL301786B2 (en) 2016-10-28 2025-09-01 Morphosys Ag Combination of anti-CD19 antibody with BCL-2 inhibitor and their uses
HRP20231229T1 (hr) 2017-05-31 2024-02-02 Morphosys Ag Paradigma liječenja za protutijelo anti-cd19 i venetoklaks kombinacijsko liječenje
GB201809746D0 (en) * 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
CN112638392B (zh) * 2018-08-31 2024-09-10 Adc治疗有限公司 组合疗法
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
EP4051317A1 (en) * 2019-10-31 2022-09-07 MorphoSys AG Sequential anti-cd19 therapy
US20220389104A1 (en) * 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013024095A1 (en) 2011-08-16 2013-02-21 Morphosys Ag Combination therapy with an anti - cd19 antibody and a purine analog
WO2013024097A1 (en) 2011-08-16 2013-02-21 Morphosys Ag Combination therapy with an anti - cd19 antibody and a nitrogen mustard
WO2015130585A1 (en) 2014-02-28 2015-09-03 Merck Sharp & Dohme Corp. Method for treating cancer
WO2016130902A1 (en) 2015-02-12 2016-08-18 Seattle Genetics, Inc. Combination therapy using a cd19-adc and vincristine

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
CA2422076A1 (en) 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
EP2054335B1 (en) 2006-08-15 2012-04-04 Hydralift Amclyde, Inc. Direct acting single sheave active/passiv heave compensator
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
RU2476441C2 (ru) 2007-10-19 2013-02-27 Сиэтл Дженетикс, Инк. Cd19-связывающие средства и их применение
US20100128586A1 (en) 2008-11-25 2010-05-27 Mediatek Inc. Method and apparatus for accessing data from disc with linking area
EP2398829A2 (en) 2009-02-23 2011-12-28 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2445530B1 (en) 2009-06-24 2016-09-07 The Feinstein Institute for Medical Research Method for treating chronic lymphocytic leukemia
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
CN107898791A (zh) 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
US8543911B2 (en) 2011-01-18 2013-09-24 Apple Inc. Ordering document content based on reading flow
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
WO2015082583A1 (en) * 2013-12-05 2015-06-11 F. Hoffmann-La Roche Ag Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
AU2015244039B2 (en) * 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
JP2017519757A (ja) 2014-06-16 2017-07-20 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． 慢性リンパ球性白血病（ｃｌｌ）の処置
BR112017008042A2 (pt) 2014-10-20 2017-12-26 Juno Therapeutics Inc métodos e composições para dosagem em terapia de célula adotiva
LT3302550T (lt) 2015-05-26 2019-11-11 Morphosys Ag Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas
PT3302549T (pt) 2015-05-26 2019-09-09 H Hoffnabb La Roche Ag Terapêutica combinada de um anticorpo anti-cd20 com um inibidor de bcl-2 e um inibidor de mdm2
EP3316888A1 (en) 2015-07-02 2018-05-09 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
SMT202100541T1 (it) 2015-08-21 2021-11-12 Morphosys Ag Combinazioni e loro usi
RS62155B1 (sr) 2016-05-30 2021-08-31 Morphosys Ag Postupci predviđanja terapijske koristi anti-cd19 terapije kod pacijenata
SI3475303T1 (sl) 2016-06-27 2021-12-31 Morphosys Ag Formulacija protitelesa proti CD19
IL301786B2 (en) 2016-10-28 2025-09-01 Morphosys Ag Combination of anti-CD19 antibody with BCL-2 inhibitor and their uses
HRP20231229T1 (hr) * 2017-05-31 2024-02-02 Morphosys Ag Paradigma liječenja za protutijelo anti-cd19 i venetoklaks kombinacijsko liječenje
US20210292410A1 (en) 2017-12-07 2021-09-23 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
MX2021013101A (es) 2019-05-03 2022-01-04 Morphosys Ag Terapia anti-cd19 en pacientes que tienen una cantidad limitada de células nk.
TWI865644B (zh) 2019-10-31 2024-12-11 德商莫菲西斯公司 用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合
US20210130461A1 (en) 2019-10-31 2021-05-06 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells
EP4051317A1 (en) 2019-10-31 2022-09-07 MorphoSys AG Sequential anti-cd19 therapy
US20230014026A1 (en) 2020-06-22 2023-01-19 Morphosys Ag Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint
US20220184208A1 (en) 2020-12-04 2022-06-16 Morphosys Ag Anti-cd19 combination therapy
TW202334231A (zh) 2021-12-22 2023-09-01 德商莫菲西斯公司 抗cd19抗體療法的治療範例

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013024095A1 (en) 2011-08-16 2013-02-21 Morphosys Ag Combination therapy with an anti - cd19 antibody and a purine analog
WO2013024097A1 (en) 2011-08-16 2013-02-21 Morphosys Ag Combination therapy with an anti - cd19 antibody and a nitrogen mustard
WO2015130585A1 (en) 2014-02-28 2015-09-03 Merck Sharp & Dohme Corp. Method for treating cancer
WO2016130902A1 (en) 2015-02-12 2016-08-18 Seattle Genetics, Inc. Combination therapy using a cd19-adc and vincristine

Also Published As

Publication number Publication date
US12358983B2 (en) 2025-07-15
WO2018078123A1 (en) 2018-05-03
MX2022016270A (es) 2023-02-15
JP2024167208A (ja) 2024-12-03
EP3532098A1 (en) 2019-09-04
EP3532098B1 (en) 2021-04-07
RU2019113370A (ru) 2020-11-30
IL301786A (en) 2023-05-01
JP2022137089A (ja) 2022-09-21
MX2019004942A (es) 2019-08-12
AU2017348624A1 (en) 2019-03-28
AU2017348624B2 (en) 2024-09-26
PT3532098T (pt) 2021-06-17
CN109890418B (zh) 2024-03-08
SG10202104036QA (en) 2021-05-28
DK3532098T3 (da) 2021-05-25
BR112019008244A2 (pt) 2019-07-16
IL266216B1 (en) 2023-05-01
IL301786B2 (en) 2025-09-01
CY1124648T1 (el) 2022-07-22
HUE054496T2 (hu) 2021-09-28
PL3532098T3 (pl) 2022-01-31
RU2756405C2 (ru) 2021-09-30
LT3532098T (lt) 2021-06-25
EP3903821A1 (en) 2021-11-03
HRP20210838T1 (hr) 2021-08-06
IL301786B1 (en) 2025-05-01
IL320372A (en) 2025-06-01
KR20190075942A (ko) 2019-07-01
US20190241656A1 (en) 2019-08-08
ES2871574T3 (es) 2021-10-29
AU2024287178A1 (en) 2025-01-23
JP2019533682A (ja) 2019-11-21
IL266216A (en) 2019-06-30
NZ751414A (en) 2025-10-31
CA3037246A1 (en) 2018-05-03
KR20230028571A (ko) 2023-02-28
SI3532098T1 (sl) 2021-12-31
RS62036B1 (sr) 2021-07-30
SMT202100347T1 (it) 2021-07-12
RU2019113370A3 (https=) 2021-03-01
CN118045175A (zh) 2024-05-17
CN109890418A (zh) 2019-06-14
JP7094950B2 (ja) 2022-07-04
ZA201903302B (en) 2021-04-28
IL266216B2 (en) 2023-09-01

Similar Documents

Publication Publication Date Title
AU2022202796B2 (en) Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof
KR102500868B1 (ko) 항-cd19 항체 및 bcl-2 억제제의 조합 및 이의 용도
US20250195646A1 (en) Combinations and uses thereof
HK40064491A (en) Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
HK40014532B (en) Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
HK40014532A (en) Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
NZ793707A (en) Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190430

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201026

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220512

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20221111

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230213

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230214

End annual number: 3

Start annual number: 1

PG1601 Publication of registration